U.S. Markets close in 4 hrs 58 mins
  • S&P 500

    3,690.68
    +23.96 (+0.65%)
     
  • Dow 30

    30,139.67
    +170.15 (+0.57%)
     
  • Nasdaq

    12,425.70
    +48.52 (+0.39%)
     
  • Russell 2000

    1,871.86
    +23.16 (+1.25%)
     
  • Crude Oil

    45.98
    +0.34 (+0.74%)
     
  • Gold

    1,835.80
    -5.30 (-0.29%)
     
  • Silver

    24.14
    -0.00 (-0.01%)
     
  • EUR/USD

    1.2149
    0.0000 (-0.0000%)
     
  • 10-Yr Bond

    0.9810
    +0.0610 (+6.63%)
     
  • Vix

    20.82
    -0.46 (-2.16%)
     
  • GBP/USD

    1.3472
    +0.0019 (+0.1442%)
     
  • USD/JPY

    104.1700
    +0.3100 (+0.2985%)
     
  • BTC-USD

    18,983.08
    -274.51 (-1.43%)
     
  • CMC Crypto 200

    372.30
    -6.94 (-1.83%)
     
  • FTSE 100

    6,554.05
    +63.78 (+0.98%)
     
  • Nikkei 225

    26,751.24
    -58.13 (-0.22%)
     

Biofrontera to present at the Baader Investment Conference

Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced that Prof. Dr. Hermann Lübbert, Biofrontera’s CEO, will be presenting at the Baader Investment Conference. The conference will take place from September 23-27, 2019 at the Sofitel Munich Bayerpost in Munich, Germany.

Biofrontera's management team will be available for one-on-one meetings with investors who are registered to attend the event.

Details for the presentation are as follows:

Date: Friday, September 27, 2019
Time: 10:00 AM CEST
Venue: Sofitel Munich Bayerpost, Forum 2

-End-

For enquiries, please contact:



Biofrontera AG
Thomas Schaffer, Chief Financial Officer





+49 (0) 214 87 63 2 0
ir@biofrontera.com

IR UK: Seton Services
Toni Vallen



+44 (0) 207 229 0805

IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas



+1 646-536-7035
+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company’s lead product is the combination of Ameluz®, a topical prescription drug, and medical device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets Xepi, a prescription medication for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.